{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:47:48Z","timestamp":1791992868179,"version":"4.4.0"},"reference-count":198,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.annonc.2026.10.101","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:15:24Z","timestamp":1791990924000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging Therapeutic targets and Early-phase drug Development in Gynecological Malignancies"],"prefix":"10.1016","author":[{"given":"K.","family":"Ouali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DSP.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lheureux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Massard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2026.10.101_bib1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/ijgo.70279","article-title":"Global determinants of gynecologic cancer incidence and mortality: A cluster\u2010based analysis with predictive insights","volume":"171","author":"Cuello","year":"2025","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.annonc.2026.10.101_bib2","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.14.04155","article-title":"Global burden of gynaecological cancers in 2022 and projections to 2050","volume":"14","author":"Zhu","year":"2024","journal-title":"J Glob Health"},{"key":"10.1016\/j.annonc.2026.10.101_bib3","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.annonc.2021.02.015","article-title":"The systemic treatment of recurrent ovarian cancer revisited","volume":"32","author":"Baert","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib4","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ygyno.2022.02.024","article-title":"Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification","volume":"165","author":"Siegenthaler","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100579","article-title":"Recurrent or primary metastatic cervical cancer: current and future treatments","volume":"7","author":"Gennigens","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.annonc.2026.10.101_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1633410","article-title":"Genomic instability and CCNE1 amplification as emerging biomarkers for stratifying high-grade serous ovarian cancer","volume":"15","author":"Conca","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Levine","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2026.10.101_bib8","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41571-024-00904-z","article-title":"Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination","volume":"21","author":"Malag\u00f3n","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.annonc.2026.10.101_bib9","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/bjc.2015.395","article-title":"PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions","volume":"113","author":"Ledermann","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2026.10.101_bib10","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11523-023-00970-w","article-title":"PARP Inhibitors in Ovarian Cancer: A Review","volume":"18","author":"O\u2019Malley","year":"2023","journal-title":"Target Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib11","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2026.10.101_bib12","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2026.10.101_bib13","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab Plus Carboplatin\/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial","volume":"42","author":"Westin","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib14","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2026.10.101_bib15","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab Soravtansine in FR\u03b1-Positive, Platinum-Resistant Ovarian Cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2026.10.101_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib17","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.it.2024.12.006","article-title":"Immune evasion in ovarian cancer: implications for immunotherapy and emerging treatments","volume":"46","author":"Gupta","year":"2025","journal-title":"Trends Immunol"},{"key":"10.1016\/j.annonc.2026.10.101_bib18","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41571-024-00937-4","article-title":"Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach","volume":"21","author":"Ghisoni","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib19","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"key":"10.1016\/j.annonc.2026.10.101_bib21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-025-01752-9","article-title":"Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies","volume":"18","author":"Zhou","year":"2025","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib23","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(26)00602-1","article-title":"Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65\/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study","volume":"407","author":"Colombo","year":"2026","journal-title":"The Lancet"},{"key":"10.1016\/j.annonc.2026.10.101_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.labinv.2025.104249","article-title":"Assessing the Status of Cyclin E1 (CCNE1) From Gene to Protein Level in Ovarian and Endometrial Carcinomas: A Systematic Review","volume":"105","author":"Trecourt","year":"2025","journal-title":"Lab Invest"},{"key":"10.1016\/j.annonc.2026.10.101_bib25","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1007\/s12672-025-04032-7","article-title":"Multiomic analysis of CCNE1 amplification associated molecular and immune features in gynecological cancers","volume":"16","author":"Liu","year":"2025","journal-title":"Discov Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib26","first-page":"1014","article-title":"Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma","volume":"27","author":"Kuhn","year":"2014","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"key":"10.1016\/j.annonc.2026.10.101_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1445128","article-title":"Race- associated molecular differences in uterine serous carcinoma","volume":"14","author":"Lara","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib28","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/diagnostics10050279","article-title":"CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer","volume":"10","author":"Gorski","year":"2020","journal-title":"Diagnostics"},{"key":"10.1016\/j.annonc.2026.10.101_bib29","doi-asserted-by":"crossref","first-page":"5965","DOI":"10.3390\/cancers14235965","article-title":"Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian Cancer","volume":"14","author":"van Wagensveld","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.annonc.2026.10.101_bib30","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/cncr.34582","article-title":"CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study","volume":"129","author":"Kang","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2026.10.101_bib31","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/cjp2.168","article-title":"Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma","volume":"6","author":"Chan","year":"2020","journal-title":"J Pathol Clin Res"},{"key":"10.1016\/j.annonc.2026.10.101_bib32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ygyno.2025.03.086","article-title":"Impact of CCNE1 amplification on molecular signatures and patient outcomes in high-grade serous ovarian and endometrial cancer","volume":"200","author":"George","year":"2025","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib33","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10637-023-01371-6","article-title":"A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors","volume":"41","author":"Falchook","year":"2023","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.annonc.2026.10.101_bib34","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/1078-0432.CCR-21-0158","article-title":"Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study","volume":"28","author":"Moore","year":"2022","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.annonc.2026.10.101_bib35","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1200\/JCO.22.00830","article-title":"Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification","volume":"41","author":"Fu","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib36","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1200\/JCO-24-01606","article-title":"ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma","volume":"43","author":"Liu","year":"2025","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ygyno.2025.03.060","article-title":"Cyclin E1 as a predictive biomarker of azenosertib benefit in platinum-resistant ovarian cancer: Outcomes from part 1b of the DENALI study (GOG-3066)","volume":"200","author":"Simpkins","year":"2025","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib38","doi-asserted-by":"crossref","first-page":"CT065","DOI":"10.1158\/1538-7445.AM2026-CT065","article-title":"Abstract CT065: Preliminary safety, pharmacokinetics and pharmacodynamics of SGR-3515, a Wee1\/Myt1 dual inhibitor from an ongoing Phase 1 study in participants with advanced solid tumors (SGR-3515-101)","volume":"86","author":"Lheureux","year":"2026","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.10.101_bib39","doi-asserted-by":"crossref","first-page":"CT262","DOI":"10.1158\/1538-7445.AM2025-CT262","article-title":"Abstract CT262: Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656)","volume":"85","author":"Schram","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.10.101_bib40","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2026-CT022","article-title":"Abstract CT022: First data disclosure of the Phase I trial of the first in class combination of WEE1 inhibitor zedoresertib with PKMYT1 inhibitor lunresertib in patients with advanced solid tumors harboring CCNE1, FBXW7, or PPP2R1A genomic alterations","volume":"86","author":"Yap","year":"2026","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.10.101_bib41","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcad039","article-title":"CDK2 regulates collapsed replication fork repair in CCNE1-amplified ovarian cancer cells via homologous recombination","volume":"5","author":"Brown","year":"2023","journal-title":"NAR Cancer"},{"key":"10.1016\/j.annonc.2026.10.101_bib42","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1158\/0008-5472.CAN-24-2360","article-title":"Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors","volume":"85","author":"House","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.10.101_bib43","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.5514","article-title":"Safety and preliminary efficacy from a phase 1 study of INCB123667, a selective CDK2 inhibitor, in patients with advanced platinum-resistant and refractory ovarian cancer (OC)","volume":"43","author":"Damian","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib44","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.5603","article-title":"Interim safety and antitumor activity data from a phase 1 study of INCB123667, a selective CDK2 inhibitor, in patients with metastatic recurrent endometrial cancer","volume":"43","author":"Lorusso","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib45","article-title":"BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation","volume":"41","author":"Patel","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib46","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1016\/j.annonc.2024.08.044","article-title":"35P The selective WEE1 inhibitor azenosertib shows synergistic anti-tumor effects in combination with topoisomerase I inhibitor-based antibody drug conjugates","volume":"35","author":"Ma","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib47","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1158\/1078-0432.CCR-22-2630","article-title":"Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305","volume":"29","author":"Kinneer","year":"2023","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.annonc.2026.10.101_bib48","volume":"41","author":"Liu","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib49","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib50","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10555-025-10283-1","article-title":"Hematological toxicity of parp inhibitors in solid tumors: a systematic review and safety meta-analysis","volume":"44","author":"Maiorano","year":"2025","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.annonc.2026.10.101_bib51","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_390876","article-title":"Managing Adverse Effects Associated With Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World Data","author":"Friedlander","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.annonc.2026.10.101_bib52","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2022-CT007","article-title":"Abstract CT007: PETRA: First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1\/2, PALB2 or RAD51C\/D mutations","volume":"82","author":"Yap","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.10.101_bib53","doi-asserted-by":"crossref","first-page":"S565","DOI":"10.1016\/j.annonc.2025.08.1492","article-title":"923MO First results from a phase I trial of SNV1521, a next generation, CNS-penetrant, PARP1-selective inhibitor in patients (pts) with molecularly selected advanced solid tumors","volume":"36","author":"Yap","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib54","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.3122","article-title":"Safety and efficacy of EIK1003, a selective PARP1 inhibitor, as monotherapy in participants with advanced solid tumors","volume":"43","author":"Sonpavde","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib55","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.16_suppl.3102","article-title":"EIK1003, a PARP1-selective inhibitor, in combination with paclitaxel (PTX): Initial combination and updated monotherapy results from a phase 1\/2 study EIK1003-001 in advanced solid tumors","volume":"44","author":"Hojgaard","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib56","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.3154","article-title":"A phase 1 study of HRS-1167 (M9466), a highly selective PARP1 inhibitor, in patients (pts) with advanced solid tumors","volume":"42","author":"Wu","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib57","doi-asserted-by":"crossref","first-page":"CT064","DOI":"10.1158\/1538-7445.AM2026-CT064","article-title":"Abstract CT064: Updated results from a first-in-human phase 1,2 study of ACE-106, a highly selective and potentially best-in-class PARP1 inhibitor in advanced solid tumors","volume":"86","author":"Cai","year":"2026","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.10.101_bib58","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2026.10.101_bib59","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41586-019-1102-x","article-title":"WRN helicase is a synthetic lethal target in microsatellite unstable cancers","volume":"568","author":"Chan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2026.10.101_bib60","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41586-024-07350-y","article-title":"Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers","volume":"629","author":"Ferretti","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2026.10.101_bib61","doi-asserted-by":"crossref","first-page":"S567","DOI":"10.1016\/j.annonc.2025.08.1494","volume":"36","author":"Foote","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib62","first-page":"1","article-title":"Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial","author":"Yap","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2026.10.101_bib63","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41416-023-02141-0","article-title":"Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry","volume":"128","author":"Vermij","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2026.10.101_bib64","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ygyno.2024.12.003","article-title":"Palbociclib plus letrozole in estrogen receptor-positive advanced\/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3\/PALEO trial","volume":"192","author":"Mirza","year":"2025","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib65","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.22.00628","article-title":"A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer","volume":"41","author":"Konstantinopoulos","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib66","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000926","article-title":"Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers","volume":"5","author":"Colon-Otero","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.annonc.2026.10.101_bib67","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/EDBK_281085","article-title":"Selective CDK4\/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic Biomarkers","author":"Knudsen","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.annonc.2026.10.101_bib68","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.3108","article-title":"First-in-human phase 1\/2a study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060 + endocrine therapy (ET): Updated safety data in patients with HR+\/HER2\u2212 mBC","volume":"42","author":"Giordano","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib69","doi-asserted-by":"crossref","unstructured":"Campone M, Laurentiis MD, Jhaveri K, et al. Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer. N Engl J Med; 0. DOI: 10.1056\/NEJMoa2505725.","DOI":"10.1056\/NEJMoa2505725"},{"key":"10.1016\/j.annonc.2026.10.101_bib70","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2026.10.101_bib71","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/annonc\/mdy081","article-title":"ESR1 and endocrine therapy resistance: more than just mutations","volume":"29","author":"Piscuoglio","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib72","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/1078-0432.CCR-25-2758","article-title":"ESR1 Mutation in Endocrine Treatment-Na\u00efve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial","volume":"32","author":"Blanc-Durand","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2026.10.101_bib73","first-page":"1269","article-title":"Genomic landscape of endometrial carcinomas of no specific molecular profile","volume":"35","author":"Momeni-Boroujeni","year":"2022","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"key":"10.1016\/j.annonc.2026.10.101_bib74","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/709736","article-title":"Molecular Alterations of PI3K\/Akt\/mTOR Pathway: A Therapeutic Target in Endometrial Cancer","volume":"2014","author":"Pavlidou","year":"2014","journal-title":"Sci World J"},{"key":"10.1016\/j.annonc.2026.10.101_bib75","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1002\/cncr.25515","article-title":"A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma","volume":"116","author":"Slomovitz","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2026.10.101_bib76","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1200\/JCO.2010.34.1578","article-title":"Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group","volume":"29","author":"Oza","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib77","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamaoncol.2022.1047","article-title":"Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1\/2 Randomized Clinical Trial","volume":"8","author":"Heudel","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib78","doi-asserted-by":"crossref","unstructured":"Ray-Coquard IL, Miller R, Brown J, et al. 69O Novel regimens for persistent\/recurrent rare epithelial ovarian carcinomas (EOCs) selected according to biomarker status: ENGOT-GYN2\/GOG-3051\/BOUQUET phase II study results. ESMO Open; 10. Epub ahead of print 1 June 2025. DOI: 10.1016\/j.esmoop.2025.105199.","DOI":"10.1016\/j.esmoop.2025.105199"},{"key":"10.1016\/j.annonc.2026.10.101_bib79","doi-asserted-by":"crossref","unstructured":"Wu X, Yonemori K, Niimi K, et al. GLOBAL PHASE II STUDY OF RISOVALISIB, A SELECTIVE PI3K\u03b1 INHIBITOR, AS MONOTHERAPY IN PATIENTS WITH RECURRENT\/PERSISTENT OVARIAN CLEAR CELL CARCINOMA HARBORING PIK3CA HOTSPOT MUTATIONS. Int J Gynecol Cancer; 35. Epub ahead of print 1 November 2025. DOI: 10.1016\/j.ijgc.2025.102737.","DOI":"10.1016\/j.ijgc.2025.102737"},{"key":"10.1016\/j.annonc.2026.10.101_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.2266","article-title":"LBA27 First-in-human results of STX-478, a mutant-selective PI3Ka inhibitor, in advanced solid tumor patients","volume":"35","author":"Montero","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib81","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ygyno.2009.09.038","article-title":"AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma","volume":"116","author":"Cohen","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib82","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/sj.bjc.6605109","article-title":"The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas","volume":"101","author":"Shoji","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2026.10.101_bib83","doi-asserted-by":"crossref","unstructured":"Crespo NA, Reddy S, Ross J, et al. 945 TP53 Y220C Alterations in Ovarian Carcinomas. Lab Invest; 105. Epub ahead of print 1 March 2025. DOI: 10.1016\/j.labinv.2024.103179.","DOI":"10.1016\/j.labinv.2024.103179"},{"key":"10.1016\/j.annonc.2026.10.101_bib84","doi-asserted-by":"crossref","unstructured":"Gaughran G, Body A, Thavaneswaran S, et al. 82P Y220C, a rare but druggable TP53 mutation: A molecular landscape in an Australian context. ESMO Open; 10. Epub ahead of print 1 August 2025. DOI: 10.1016\/j.esmoop.2025.105432.","DOI":"10.1016\/j.esmoop.2025.105432"},{"key":"10.1016\/j.annonc.2026.10.101_bib85","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1056\/NEJMoa2508820","article-title":"Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors","volume":"394","author":"Dumbrava","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2026.10.101_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.103070","article-title":"Rezatapopt, a selective p53 reactivator, in advanced or metastatic solid tumours with a TP53 Y220C mutation: interim efficacy results from patients with ovarian cancer in the phase 2 PYNNACLE trial","volume":"36","author":"Frenel","year":"2026","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.annonc.2026.10.101_bib87","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.ygyno.2026.01.058","article-title":"The pivotal PYNNACLE phase 2 trial assessing rezatapopt, a selective p53 reactivator, in patients with advanced or metastatic solid tumors harboring a TP53 Y220C mutation: Interim analysis of patients with ovarian cancer","volume":"208","author":"Schram","year":"2026","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib88","doi-asserted-by":"crossref","first-page":"7092","DOI":"10.1158\/1538-7445.AM2026-7092","article-title":"Abstract 7092: Highly potent and mutant-selective p53 Y220C reactivators with best-in-class potential","volume":"86","author":"Lin","year":"2026","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.10.101_bib89","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1158\/1538-7445.AM2026-4578","article-title":"Abstract 4578: Discovery of a Best-in-Class small molecule p53 Y220C reactivator: Breaking through the potency ceiling","volume":"86","author":"Boon","year":"2026","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.10.101_bib90","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1158\/1538-7445.AM2026-4572","article-title":"Abstract 4572: Discovery of SY-14556, a highly potent and selective small molecule reactivator of p53 Y220C mutant with differentiated preclinical profile","volume":"86","author":"Li","year":"2026","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.10.101_bib91","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2026-CT290","article-title":"Abstract CT290: NTS071-101: A phase 1\/2a study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of NTS071 in patients with advanced solid tumors harboring a TP53 Y220C mutation","volume":"86","author":"Shen","year":"2026","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.10.101_bib92","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1158\/1078-0432.CCR-21-4183","article-title":"MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma","volume":"28","author":"Manning-Geist","year":"2022","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.annonc.2026.10.101_bib93","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO-25-00112","article-title":"Efficacy and Safety of Avutometinib \u00b1 Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60\/GOG-3052\/RAMP 201","volume":"43","author":"Banerjee","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib94","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ygyno.2024.10.026","article-title":"KRAS mutations in endometrial cancers: Possible prognostic and treatment implications","volume":"191","author":"Kilowski","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib95","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.3802\/jgo.2018.29.e4","article-title":"Mutational analysis of KRAS and its clinical implications in cervical cancer patients","volume":"29","author":"Jiang","year":"2018","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib96","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3390\/cells14161232","article-title":"Recent Therapies and Biomarkers in Mucinous Ovarian Carcinoma","volume":"14","author":"Przywara","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.annonc.2026.10.101_bib97","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"Langen","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.annonc.2026.10.101_bib98","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(25)00866-9","article-title":"Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial","volume":"406","author":"Barlesi","year":"2025","journal-title":"The Lancet"},{"key":"10.1016\/j.annonc.2026.10.101_bib99","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.2_suppl.654","article-title":"Preliminary phase 1 results of INCB161734, a novel oral Kirsten rat sarcoma (KRAS) G12D inhibitor, as monotherapy or in combination with chemotherapy for advanced\/metastatic pancreatic duct adenocarcinoma (PDAC)","volume":"44","author":"Wainberg","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.2531","article-title":"Trial in progress: A phase 1, first-in-human, open-label, multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations","volume":"41","author":"Tolcher","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib101","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.ccell.2025.05.016","article-title":"A first-in-class EGFR-directed KRAS G12V selective inhibitor","volume":"43","author":"Stanland","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.annonc.2026.10.101_bib102","doi-asserted-by":"crossref","first-page":"ND06","DOI":"10.1158\/1538-7445.AM2025-ND06","article-title":"Abstract ND06: Discovery of RMC-5127, an oral, RAS (ON) G12V-selective, noncovalent, tri-complex inhibitor","volume":"85","author":"Edwards","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.10.101_bib103","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2605555","article-title":"Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer","volume":"395","author":"O\u2019Reilly","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2026.10.101_bib104","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1158\/1538-7445.AM2026-5866","article-title":"Abstract 5866: Preclinical combination approaches with the pan-KRAS inhibitor AMG 410 in KRAS-mutant cancers","volume":"86","author":"Chen","year":"2026","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.10.101_bib105","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1158\/1538-7445.AM2026-418","article-title":"Abstract 418: ETX-929, a potential best-In-class, oral, highly potent and selective dual ON\/OFF state Pan-KRAS small molecule inhibitor for the treatment of KRAS mutant and wild-type amplified cancers","volume":"86","author":"Kulkarni","year":"2026","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.10.101_bib106","doi-asserted-by":"crossref","first-page":"7104","DOI":"10.1158\/1538-7445.AM2026-7104","article-title":"Abstract 7104: BBO-11818: An orally bioavailable, highly potent and selective non-covalent pan-KRAS(ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models","volume":"86","author":"Stahlhut Espinosa","year":"2026","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.10.101_bib107","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41467-024-55300-z","article-title":"Targeting chromosomally unstable tumors with a selective KIF18A inhibitor","volume":"16","author":"Phillips","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2026.10.101_bib108","article-title":"A first-in-human study of ATX-295, an oral inhibitor of KIF18A, in patients with advanced or metastatic solid tumors, including ovarian cancer","volume":"44","author":"Wang","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib109","doi-asserted-by":"crossref","first-page":"7094","DOI":"10.1158\/1538-7445.AM2026-7094","article-title":"Abstract 7094: Discovery of QLS1303, a potent and selective KIF18A inhibitor with robust anti-tumor activity in CIN+ preclinical cancer models","volume":"86","author":"Chen","year":"2026","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.10.101_bib110","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.OVARIAN25-B024","article-title":"Abstract B024: Investigating a novel KIF18A inhibitor ATX020 in chromosomally instable ovarian cancer","volume":"85","author":"Nair","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.10.101_bib111","doi-asserted-by":"crossref","unstructured":"Secord AA, Lee E, Sundborg M, et al. A PHASE 3, OPEN-LABEL RANDOMIZED TRIAL TO COMPARE RINATABART SESUTECAN VERSUS INVESTIGATOR\u2019S CHOICE OF CHEMOTHERAPY IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER: RAINFOLTM-02 (ENGOT-OV86\/GOG-3107). Int J Gynecol Cancer; 35. Epub ahead of print 1 November 2025. DOI: 10.1016\/j.ijgc.2025.102614.","DOI":"10.1016\/j.ijgc.2025.102614"},{"key":"10.1016\/j.annonc.2026.10.101_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2024.07.453","volume":"190","author":"Naumann","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib113","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2313811","article-title":"Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer","volume":"391","author":"Vergote","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2026.10.101_bib114","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib115","doi-asserted-by":"crossref","first-page":"S547","DOI":"10.1016\/j.annonc.2024.08.776","article-title":"714MO Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): Results from the phase II TROPION-PanTumor03 study","volume":"35","author":"Oaknin","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib116","article-title":"715MO Safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a phase II study","volume":"35","author":"Wang","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib117","doi-asserted-by":"crossref","first-page":"S693","DOI":"10.1016\/j.annonc.2025.08.1748","article-title":"1111P Sacituzumab tirumotecan (Sac-TMT) monotherapy in advanced\/metastatic endometrial carcinoma (EC): Results from a phase I\/II study (MK-2870-001\/KL264-01)","volume":"36","author":"Wang","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib118","article-title":"1168P Efficacy and safety of sacituzumab tirumotecan (Sac-TMT) monotherapy in advanced\/metastatic cervical cancer: Results from a phase I\/II study (MK-2870-001\/KL264-01)","volume":"36","author":"Wang","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2016.06.011","article-title":"B7-H4 Expression in Ovarian Serous Carcinoma: A Study of 306 Cases","volume":"57","author":"Liang","year":"2016","journal-title":"Hum Pathol"},{"key":"10.1016\/j.annonc.2026.10.101_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.108157","article-title":"110RO Mocertatug rezetecan (Mo-Rez), a B7-H4-targeted antibody\u2013drug conjugate (ADC), in platinum-resistant ovarian cancer (PROC) and endometrial cancer (EC): Additional data from BEHOLD-1 study","volume":"11","author":"Ray-Coquard","year":"2026","journal-title":"ESMO Open"},{"key":"10.1016\/j.annonc.2026.10.101_bib121","doi-asserted-by":"crossref","first-page":"S485","DOI":"10.1016\/j.annonc.2024.08.673","article-title":"606O Initial results from a first-in-human study of the B7-H4-directed antibody-drug conjugate (ADC) AZD8205 (puxitatug samrotecan) in patients with advanced\/metastatic solid tumors","volume":"35","author":"Meric-Bernstam","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/S0090-8258(22)01432-9","article-title":"Clinical significance of cadherin-6 expression in primary and recurrent epithelial ovarian cancer and its association with outcomes: A potential therapeutic target for epithelial ovarian cancer (206)","volume":"166","author":"Shintani","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib123","doi-asserted-by":"crossref","first-page":"S1585","DOI":"10.1016\/j.annonc.2025.09.054","article-title":"LBA42 Raludotatug deruxtecan (R-DXd) in patients (pts) with platinum-resistant ovarian cancer (PROC): Primary analysis of the phase II dose-optimization part of REJOICE-Ovarian01","volume":"36","author":"Ray-Coquard","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib124","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3892\/mmr.2021.12316","article-title":"Claudin 6: Therapeutic prospects for tumours, and mechanisms of expression and regulation","volume":"24","author":"Du","year":"2021","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.annonc.2026.10.101_bib125","doi-asserted-by":"crossref","first-page":"S488","DOI":"10.1016\/j.annonc.2024.08.677","article-title":"610O Preliminary results from a phase I, first-in-human study of DS-9606a, a claudin 6 (CLDN6)-directed antibody-drug conjugate (ADC), in patients (pts) with tumor types known to express CLDN6","volume":"35","author":"Patel","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib126","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1448695","article-title":"PTK7: an underestimated contributor to human cancer","volume":"14","author":"Jin","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114209","article-title":"Identification of the extracellular membrane protein ENPP3 as a major cGAMP hydrolase and innate immune checkpoint","volume":"43","author":"Mardjuki","year":"2024","journal-title":"Cell Rep"},{"key":"10.1016\/j.annonc.2026.10.101_bib128","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12885-025-13461-0","article-title":"The role of MUC16 in tumor biology and tumor immunology in ovarian cancer","volume":"25","author":"Yang","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.annonc.2026.10.101_bib129","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ygyno.2012.08.017","article-title":"A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer","volume":"127","author":"Fauci","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib130","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ygyno.2011.09.012","article-title":"Immunoexpression of B7-H3 in endometrial cancer: relation to tumor T-cell infiltration and prognosis","volume":"124","author":"Brunner","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib131","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.7150\/jca.24959","article-title":"Roles of B7-H3 in Cervical Cancer and Its Prognostic Value","volume":"9","author":"Han","year":"2018","journal-title":"J Cancer"},{"key":"10.1016\/j.annonc.2026.10.101_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.10.1040","article-title":"603O DB-1311\/BNT324 (a novel B7H3 ADC) in patients with advanced cervical cancer or platinum-resistant recurrent ovarian cancer","volume":"36","author":"Chang","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib133","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12905-025-04227-8","article-title":"Exploring Nectin-4 as a potential diagnostic biomarker in endometrial adenocarcinoma","volume":"26","author":"Ordu","year":"2025","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.annonc.2026.10.101_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.155913","article-title":"Theranostic implications of Nectin-4 oncoprotein in gynecologic cancers: A review","volume":"269","author":"Hooks","year":"2025","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.annonc.2026.10.101_bib135","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.16_suppl.5508","article-title":"A phase 1\/2 study of the next-generation nectin-4\u2013targeting antibody-drug conjugate CRB-701 (SYS6002) in patients with recurrent or metastatic cervical cancer","volume":"44","author":"Ciuleanu","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib136","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.3018","article-title":"Preliminary results from a first-in-human phase 1 dose escalation trial of ADRX-0706, a next generation Nectin-4 ADC, in subjects with advanced solid tumors","volume":"43","author":"Drakaki","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib137","article-title":"9MW2821, a nectin-4 antibody-drug conjugate (ADC), in patients with advanced solid tumor: Results from a phase 1\/2a study","volume":"42","author":"Zhang","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib138","doi-asserted-by":"crossref","first-page":"A229","DOI":"10.1136\/ijgc-2022-igcs.524","article-title":"TP015\/#1566 A phase 2, two-stage, study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) recurrent or persistent endometrial cancer (EC)","volume":"32","author":"Porter","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.annonc.2026.10.101_bib139","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy285.157","article-title":"Mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a phase Ib study","volume":"29","author":"Matulonis","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib140","first-page":"S548","article-title":"716MO Efficacy and safety of sacituzumab tirumotecan (sac-TMT) plus pembrolizumab in patients with recurrent or metastatic cervical cancer","volume":"35","author":"Wang","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib141","doi-asserted-by":"crossref","first-page":"7172","DOI":"10.1158\/1538-7445.AM2026-7172","article-title":"Abstract 7172: Combination of B7-H4-TOP1i ADC, PD-1\/TIGIT bispecific antibody, and PARP inhibition orchestrates angiogenesis suppression and interferon-program activation in a syngeneic mouse model","volume":"86","author":"Morante-Palacios","year":"2026","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.10.101_bib142","doi-asserted-by":"crossref","unstructured":"Wang C, Yang H, Li J, et al. Mocertatug rezetecan, a B7-H4-targeted antibody-drug conjugate, in combination with bevacizumab in patients with platinum-sensitive ovarian cancer: results from a phase 1 study. Int J Gynecol Cancer; 36. Epub ahead of print 1 February 2026. DOI: 10.1016\/j.ijgc.2026.104572.","DOI":"10.1016\/j.ijgc.2026.104572"},{"key":"10.1016\/j.annonc.2026.10.101_bib143","article-title":"GLORIOSA: A randomized, open-label, phase 3 study of mirvetuximab soravtansine with bevacizumab vs. bevacizumab as maintenance in platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer","volume":"41","author":"O\u2019Malley","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib144","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ygyno.2024.01.045","article-title":"Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)\u2013targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer","volume":"185","author":"Richardson","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib145","doi-asserted-by":"crossref","first-page":"A232","DOI":"10.1136\/ijgc-2022-igcs.528","article-title":"TP019\/#1556 PICCOLO: an open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian cancers with high folate-alpha expression","volume":"32","author":"Secord","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.annonc.2026.10.101_bib146","doi-asserted-by":"crossref","first-page":"A33","DOI":"10.1136\/ijgc-2022-igcs.62","article-title":"18\/#499 Mirvetuximab soravtansine and carboplatin for treatment of patients with recurrent folate receptor alpha-positive platinum-sensitive ovarian cancer: a final analysis","volume":"32","author":"Moore","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.annonc.2026.10.101_bib147","doi-asserted-by":"crossref","unstructured":"Yuan G, Lou G, Li G, et al. Mocertatug rezetecan (a B7-H4 targeted antibody drug conjugate) in patients with heavily pre-treated platinum-sensitive ovarian cancer (PSOC): results of an open label, phase 2 study. Int J Gynecol Cancer; 36. Epub ahead of print 1 February 2026. DOI: 10.1016\/j.ijgc.2025.103069.","DOI":"10.1016\/j.ijgc.2025.103069"},{"key":"10.1016\/j.annonc.2026.10.101_bib148","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkaa026","article-title":"Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7)","volume":"4","author":"Colomban","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.annonc.2026.10.101_bib149","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2026.10.101_bib150","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2026.10.101_bib151","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved Survival with Bevacizumab in Advanced Cervical Cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2026.10.101_bib152","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1200\/JCO.21.01801","article-title":"Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","volume":"40","author":"Fu","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib153","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1158\/1538-7445.AM2025-648","article-title":"Abstract 648: Activity of BNT327\/PM8002 (PD-L1 x VEGF-A bispecific antibody) in combination with BNT325\/DB-1305 (TROP2 ADC) in solid tumors: Early preclinical and clinical evidence to support BNT327 + ADC combinations","volume":"85","author":"Hamilton","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.10.101_bib154","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008037","article-title":"Phase 1a dose escalation study of ivonescimab (AK112\/SMT112), an anti-PD-1\/VEGF-A bispecific antibody, in patients with advanced solid tumors","volume":"12","author":"Frentzas","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.annonc.2026.10.101_bib155","doi-asserted-by":"crossref","unstructured":"Coward J, Frentzas S, Mislang A, et al. 427 Efficacy and safety of AK112, an anti-PD-1\/VEGF-A bispecific antibody, in patients with platinum-resistant\/refractory epithelial ovarian cancer in a Phase 1 study. J Immunother Cancer; 9. Epub ahead of print 10 November 2021. DOI: 10.1136\/jitc-2021-SITC2021.427.","DOI":"10.1136\/jitc-2021-SITC2021.427"},{"key":"10.1016\/j.annonc.2026.10.101_bib156","doi-asserted-by":"crossref","unstructured":"Wu L, Li G, Xia B, et al. 430 A phase 1b\/II clinical study of AK112, a PD-1\/VEGF bispecific antibody, in combination with olaparib in BRCA germline wild-type platinum sensitive recurrent ovarian cancer. J Immunother Cancer; 9. Epub ahead of print 10 November 2021. DOI: 10.1136\/jitc-2021-SITC2021.430.","DOI":"10.1136\/jitc-2021-SITC2021.430"},{"key":"10.1016\/j.annonc.2026.10.101_bib157","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.5509","article-title":"Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in cervical cancer: Data from phase 1 and phase 2 studies","volume":"39","author":"Strauss","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib158","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1158\/1078-0432.CCR-23-1829","article-title":"Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent\/Recurrent\/Metastatic Cervical Cancer","volume":"30","author":"Oaknin","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2026.10.101_bib159","doi-asserted-by":"crossref","first-page":"S644","DOI":"10.1016\/j.annonc.2020.08.1018","article-title":"879TiP Phase II study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in platinum-experienced advanced cervical cancer","volume":"31","author":"Birrer","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib160","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S1470-2045(23)00411-4","article-title":"Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b\/2 trial","volume":"24","author":"Gao","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib161","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0140-6736(24)02135-4","article-title":"Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China","volume":"404","author":"Wu","year":"2024","journal-title":"The Lancet"},{"key":"10.1016\/j.annonc.2026.10.101_bib162","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.3390\/curroncol31070283","article-title":"The Complex Tumor Microenvironment in Ovarian Cancer: Therapeutic Challenges and Opportunities","volume":"31","author":"Garlisi","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib163","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1186\/s12967-025-06508-0","article-title":"Role of tumor microenvironment in ovarian cancer metastasis and clinical advancements","volume":"23","author":"Wang","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.annonc.2026.10.101_bib164","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41419-020-03009-4","article-title":"Glucocorticoids induce differentiation and chemoresistance in ovarian cancer by promoting ROR1-mediated stemness","volume":"11","author":"Karvonen","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.annonc.2026.10.101_bib165","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/S0140-6736(25)01040-2","article-title":"Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial","volume":"405","author":"Olawaiye","year":"2025","journal-title":"The Lancet"},{"key":"10.1016\/j.annonc.2026.10.101_bib166","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(26)00462-9","article-title":"Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial","volume":"407","author":"Lorusso","year":"2026","journal-title":"The Lancet"},{"key":"10.1016\/j.annonc.2026.10.101_bib167","doi-asserted-by":"crossref","first-page":"S679","DOI":"10.1016\/j.annonc.2025.08.1716","article-title":"1078P Randomised phase II study of ubamatamab \u00b1 cemiplimab in patients (pts) with platinum-resistant ovarian cancer (OC)","volume":"36","author":"Lee","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib168","doi-asserted-by":"crossref","unstructured":"Calvo E, Garcia VM, Oh D-Y, et al. 40O Phase I\/Ib open-label study of an HER2-targeted T cell engager (TCE)\u2012SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results. ESMO Open; 10. Epub ahead of print 1 March 2025. DOI: 10.1016\/j.esmoop.2025.104199.","DOI":"10.1016\/j.esmoop.2025.104199"},{"key":"10.1016\/j.annonc.2026.10.101_bib169","doi-asserted-by":"crossref","first-page":"viii408","DOI":"10.1093\/annonc\/mdy288.020","article-title":"Preliminary results from a phase I study of GBR 1302, a bispecific antibody T-cell engager, in HER2 positive cancers","volume":"29","author":"Wermke","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib170","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz8235","article-title":"Strong vaccine responses during chemotherapy are associated with prolonged cancer survival","volume":"12","author":"Melief","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.annonc.2026.10.101_bib171","doi-asserted-by":"crossref","unstructured":"Lim MC, Choi YJ, Hur S-Y, et al. GX-188E DNA vaccine plus pembrolizumab in HPV 16- and\/or 18-positive recurrent or advance cervical cancer: a phase 2 trial. eClinicalMedicine; 74. Epub ahead of print 1 August 2024. DOI: 10.1016\/j.eclinm.2024.102716.","DOI":"10.1016\/j.eclinm.2024.102716"},{"key":"10.1016\/j.annonc.2026.10.101_bib172","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/IGC.0000000000001235","article-title":"A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes-Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer","volume":"28","author":"Basu","year":"2018","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"10.1016\/j.annonc.2026.10.101_bib173","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.2638","article-title":"Randomized phase II trial evaluating the combination of TG4001, an HPV16 therapeutic vaccine, and avelumab (ave) in patients (pts) with immunotherapy-na\u00efve recurrent and\/or metastatic (R\/M) HPV16-positive cervical or anogenital cancer","volume":"43","author":"Le Tourneau","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib174","volume":"44","author":"Leary","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib175","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.2538","article-title":"Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma","volume":"37","author":"Jazaeri","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib176","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.08.1012","article-title":"873P In vivo persistence of Iovance tumour-infiltrating lymphocytes LN-145 in cervical cancer patients","volume":"31","author":"Jazaeri","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib177","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.3009","article-title":"A phase I\/II clinical trial of E6 T-cell receptor gene therapy for human papillomavirus (HPV)-associated epithelial cancers","volume":"35","author":"Hinrichs","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib178","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.3019","article-title":"Genetically engineered T-cell therapy for HPV-associated epithelial cancers: A first in human, phase I\/II clinical trial","volume":"36","author":"Doran","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib179","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1200\/JCO.18.02424","article-title":"T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, Phase I\/II Study","volume":"37","author":"Doran","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib180","doi-asserted-by":"crossref","first-page":"A472","DOI":"10.1136\/ijgc-2022-ESGO.1019","article-title":"2022-LBA-414-ESGO Preliminary clinical outcome of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced epithelial ovarian cancer","volume":"32","author":"Moore","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.annonc.2026.10.101_bib181","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","article-title":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial","volume":"29","author":"Mackensen","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2026.10.101_bib182","doi-asserted-by":"crossref","first-page":"S489","DOI":"10.1016\/j.annonc.2024.08.678","article-title":"611O Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, phase I study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed\/refractory CLDN6+ solid tumors","volume":"35","author":"Haanen","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib183","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.3390\/cancers17071060","article-title":"Artificial Intelligence in Gynecological Oncology from Diagnosis to Surgery","volume":"17","author":"Restaino","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.annonc.2026.10.101_bib184","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41698-026-01276-6","article-title":"The impact of AI on modern oncology from early detection to personalized cancer treatment","volume":"10","author":"Li","year":"2026","journal-title":"Npj Precis Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib185","first-page":"1","article-title":"Rethinking ovarian cancer III: the past decade and future directions","author":"Balkwill","year":"2026","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.annonc.2026.10.101_bib186","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.annonc.2022.03.273","article-title":"Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification","volume":"33","author":"Trapani","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib187","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.53604","article-title":"Surgical Deescalation Within Gynecologic Oncology","volume":"8","author":"Kanbergs","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.annonc.2026.10.101_bib188","doi-asserted-by":"crossref","unstructured":"Glaser G, Melamed A, Pareja R. Therapeutic de-escalation in gynecologic oncology: redefining success for patient-centered care. Int J Gynecol Cancer; 36. Epub ahead of print 1 March 2026. DOI: 10.1016\/j.ijgc.2025.104462.","DOI":"10.1016\/j.ijgc.2025.104462"},{"key":"10.1016\/j.annonc.2026.10.101_bib189","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid biopsy in cancer: current status, challenges and future prospects","volume":"9","author":"Ma","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.annonc.2026.10.101_bib190","article-title":"Advances and challenges in the use of liquid biopsy in gynaecological oncology","volume":"10","author":"Zhang","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.annonc.2026.10.101_bib191","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1002\/cncr.35381","article-title":"Clinical utility of comprehensive liquid molecular profiling in patients with advanced endometrial cancer","volume":"130","author":"Blanc-Durand","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2026.10.101_bib192","first-page":"140","article-title":"Liquid biopsy in gynecological cancers: a translational framework from molecular insights to precision oncology and clinical practice","volume":"44","author":"Martinelli","year":"2025","journal-title":"J Exp Clin Cancer Res CR"},{"key":"10.1016\/j.annonc.2026.10.101_bib193","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.08.1778","article-title":"1142P Dynamics and prognostic impact of HER3 expression in advanced ovarian cancer treated with neoadjuvant chemotherapy: Results from the CHIVA GINECO study","volume":"36","author":"Diaz","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib194","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.5591","article-title":"Folate receptor alpha (FR\u03b1; FOLR1) expression and persistence in ovarian cancer in clinical trial samples and real-world patient cohort","volume":"43","author":"Swisher","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib195","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/annonc\/mdw625","article-title":"Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC)","volume":"28","author":"Mesnage","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib196","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-25-A011","article-title":"Abstract A011: Rationale for the use of Azenosertib in Early Line Treatment of Cyclin E1-Positive High-Grade Serous Ovarian Cancer","volume":"24","author":"Abed","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.annonc.2026.10.101_bib197","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ygyno.2019.11.012","article-title":"Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies","volume":"156","author":"Vergote","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.annonc.2026.10.101_bib198","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1136\/ijgc-2024-005412","volume":"34","author":"Vergote","year":"2024","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426068833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426068833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:15:55Z","timestamp":1791990955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426068833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":198,"alternative-id":["S0923753426068833"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.10.101","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Therapeutic targets and Early-phase drug Development in Gynecological Malignancies","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.10.101","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society for Medical Oncology. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}